1075237-97-6

Basic information

• Product Name: beta-lactamase-IN-1
• Synonyms: beta-lactamase-IN-1;4-(1,3-Dihydroxypropan-2-Yl)-6-Methoxypyrido[2,3-B]Pyrazin-3(4H)-One;4-(1,3-Dihydroxypropan-2-Yl)-6-Methoxypyrido[2,3-B]Pyrazin-3(4H)-One(WXC01738)
• CAS NO: 1075237-97-6
• Molecular Formula: C11H13N3O4
• Molecular Weight: 251.23862
• Mol File: 1075237-97-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: beta-lactamase-IN-1(CAS DataBase Reference)
• NIST Chemistry Reference: beta-lactamase-IN-1(1075237-97-6)
• EPA Substance Registry System: beta-lactamase-IN-1(1075237-97-6)

Safety Data

• Hazardous Substances Data: 1075237-97-6(Hazardous Substances Data)

Usage

General Description

Beta-lactamase-IN-1 is a chemical compound that acts as an inhibitor of beta-lactamase enzymes. Beta-lactamase enzymes are responsible for antibiotic resistance in certain bacteria, as they are able to break down and inactivate beta-lactam antibiotics like penicillin. By inhibiting beta-lactamase enzymes, beta-lactamase-IN-1 can help to restore the effectiveness of beta-lactam antibiotics and improve the treatment of bacterial infections. This chemical has potential applications in the development of new antibiotics and combination therapies to combat antibiotic-resistant bacteria. Studies have shown that beta-lactamase-IN-1 is a promising candidate for further development as a therapeutic agent to address the growing concern of antibiotic resistance.

Upstream product

• 1075237-96-5 4-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)pyrido[2,3-b]pyrazin-3(4H)-one 
• 757186-96-2 2-{[6-(methyloxy)-3-nitro-2-pyridinyl]amino}-1,3-propanediol 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 1075237-91-0 N-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-3-nitro-2-pyridinamine 
• 1075237-92-1 N²-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-2,3-pyridinediamine 
• 1075237-94-3 4-(2,2-dimethyl-1,3-dioxan-5-yl)-6-(methyloxy)-1,4-dihydropyrido[2,3-b]pyrazin-3(2H)-one 
• 1075237-93-2 ethyl N-[2-[(2,2-dimethyl-1,3-dioxan-5-yl)amino]-6-(methyloxy)-3-pyridinyl]glycinate 

Downstream Products

• 1075236-89-3 gepotidacin 
• 1075234-98-8 (2R)-2-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione benzoate 
• 1075235-01-6 (2S)-2-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione benzoate 
• 1197396-96-5 2-[(4-{[2-(3,4-dichlorophenyl)ethyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione 
• 1197396-93-2 (2E)-3-(2,5-difluorophenyl)-N-{1-[(3,8-dioxo-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylen-2-yl)methyl]-4-piperidinyl}-2-propenamide 

Relevant articles and documents

Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS

Compounds of Formula (I) or a pharmaceutically acceptable salt or N-oxide thereof; Formula (I) (relative stereochemistry shown) wherein: Z1, Z2 , L are as defined, U represents a cyclic group selected from: phenyl, pyridyl, pyridazin